The standard Lorem Ipsum passage, used since the 1500s "Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" Thanks for your interest in Kalkine Media's content! To continue reading, please log in to your account or create your free account with us.Polls close in Uruguay’s election, with ruling coalition and opposition headed for photo finish
Canadian airline executives in the hot seat over carry-on bag fees say the federal government needs to reform this country's aviation system if it wants travel to become more affordable. The CEOs of Air Canada and WestJet are appearing before a parliamentary committee Friday to answer questions about their recent decisions to introduce carry-on bag fees for travellers. Air Transat and Porter Airlines also testified Friday before the standing committee on transport, infrastructure and communities. The executives faced tough questions from parliamentarians, who summoned them to testify following Air Canada's announcement earlier this month that customers paying a basic fare can only bring on a personal item and will have to check carry-on bags for a fee. Air Canada's move follows an earlier decision by WestJet to introduce an "UltraBasic" fare class that allows passengers to carry no more than a laptop bag or small backpack on board. The developments are part of an ongoing trend in the aviation sector, which has seen airlines rely increasingly on ancillary fees for formerly bundled services that range from checked bags to on-board snacks and Wi-Fi access. Committee members on Friday challenged the airline CEOs about the layers of add-on fees, arguing they are making air travel increasingly unaffordable for Canadians. "Do you truly believe this is acceptable at a time when Canadians' pocketbooks are hurting?" said Liberal MP Angelo Iacono. Another Liberal MP, Vance Badawey, challenged WestJet — a private company that does not publicly release its financial information — to open up its books and disclose its profit margins. "Because at the end of the day, that's why we're here right now," Badawey said. "We're here for affordability for the passengers." But the airline executives said by offering passengers a choice of fare categories with different service levels, they are actually making travel cheaper for Canadians. WestJet CEO Alexis von Hoensbroech said 1.2 million Canadians have chosen the airline's UltraBasic fare since it was introduced in June, resulting in lowered travel costs as that fare is on average 14 per cent lower than WestJet's next-cheapest option. "This is savings that are important in a time where there's an affordability crisis," von Hoensbroech said in an interview Friday morning. "So I think we actually do something that's good ... And I do understand the perception that is out there, but I think it's also important to share the facts." Von Hoensbroech said it's easy for politicians to be "bashing airlines" because the affordability crisis is real. But he said if the federal government really wants to lower the costs of air travel, significant reforms to the system are needed. He said air travel in Canada is among the most expensive globally, due in part to government policies and third-party fees. Navigation fees, security charges, airport improvement fees and other taxes and fees can add up to $100 to the price of a ticket, von Hoensbroech said. He said the government needs to freeze hikes in third-party fees and charges to allow Canada's aviation sector to compete globally. He also said the federal government should cease charging rent to airports for the land they sit on, allowing airports to reinvest these funds into infrastructure and services instead. This report by The Canadian Press was first published Dec. 13, 2024. Companies in this story: (TSX:AC) Amanda Stephenson, The Canadian Press
NonePalvella Therapeutics to debut on Nasdaq under the ticker symbol "PVLA" as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases Strong balance sheet with approximately $80.0 million of cash and cash equivalents, including proceeds from a PIPE financing co-led by BVF Partners, L.P. and Frazier Life Sciences Cash expected to fund operations into the second half of 2027, including through Phase 3 SELVA clinical trial of QTORINTM 3.9% rapamycin anhydrous gel (QTORINTM rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) and Phase 2 clinical trial in cutaneous venous malformations (cutaneous VMs) Microcystic LMs is a chronically debilitating and lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S. QTORINTM rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs and cutaneous VMs WAYNE, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the completion of its previously announced merger with Pieris Pharmaceuticals, Inc. (Pieris). The combined company will operate under the name Palvella Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market on December 16, 2024, under the ticker symbol "PVLA". Palvella will continue to be led by Wes Kaupinen, its Founder and Chief Executive Officer, and other members of the Palvella management team. The transaction was approved by Pieris stockholders at a special meeting held on December 11, 2024, and the transaction had been previously approved by Palvella stockholders. "With strong support from leading healthcare-dedicated investors, Palvella is well positioned to enter the public markets and pursue our vision of becoming the leading rare disease company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases," said Mr. Kaupinen. "This transaction will enable us to accelerate late-stage development of QTORINTM rapamycin, our lead product candidate, for microcystic LMs and cutaneous VMs while also further advancing additional novel product candidates from our QTORINTM platform." Concurrent with the merger, Palvella completed a previously announced oversubscribed $78.9 million private placement co-led by BVF Partners, L.P., an existing investor, and Frazier Life Sciences, a new investor, and with participation from a syndicate of leading healthcare-dedicated investors. Additional new investors include Blue Owl Healthcare Opportunities, Nantahala Capital, DAFNA Capital Management, ADAR1 Capital Management, and a healthcare dedicated fund. Existing investors Samsara BioCapital, Petrichor, CAM Capital, Ligand Pharmaceuticals, Integrated Finance Group (an AscellaHealth partner company), BioAdvance, and Gore Range Capital also participated in the financing. Palvella's cash and cash equivalents of approximately $80.0 million is expected to fund operations into the second half of 2027, including through results from the SELVA Phase 3 clinical trial of QTORINTM rapamycin for the treatment of microcystic LMs and Phase 2 clinical trial of QTORINTM rapamycin in cutaneous VMs. Palvella's research team developed QTORINTM, a patented and versatile platform designed to generate novel topical therapies that penetrate the deep layers of the skin to locally treat a broad spectrum of serious, rare genetic skin diseases. Well-accepted mechanisms of action of rapamycin and other therapeutic agents represent potential therapies for rare genetic skin diseases. However, the adverse event profile of those agents through systemic exposure poses significant barriers to patient adoption. Palvella's QTORINTM product candidates are designed for targeted, localized delivery of therapeutic agents to pathogenic tissue of interest while minimizing systemic absorption and thereby reducing the risk of unwanted adverse events associated with systemic therapy. Palvella's lead product candidate QTORINTM rapamycin is a novel, patented 3.9% rapamycin anhydrous gel currently under development for the treatment of microcystic LMs, cutaneous VMs, and other serious, functionally debilitating skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway. QTORINTM rapamycin has received FDA Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation for microcystic LMs and is the recent recipient of up to a $2.6 million FDA Orphan Products Grant. QTORINTM rapamycin has also received Fast Track Designation for venous malformations. QTORINTM rapamycin is protected by issued composition patents covering anhydrous gel formulations of rapamycin, as well as methods of use, in the U.S., Japan, Australia, China and Israel and pending patent applications broadly covering anhydrous gel formulations of rapamycin, as well as methods of use, in the U.S. and other countries. In the third quarter of 2024, Palvella initiated SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORINTM rapamycin administered once daily for the treatment of microcystic LMs. The primary efficacy endpoint is the change from baseline in the overall microcystic LM Investigator Global Assessment (mLM-IGA) at week 24. The Phase 3 study is enrolling approximately 40 subjects, age six or older, at leading vascular anomaly centers across the U.S. Transaction Details Based on the final exchange ratio of approximately 0.30946 shares of Pieris common stock for each share of Palvella common stock, at the closing of the merger, there are approximately 13.95 million shares of the combined company's common stock outstanding on a diluted basis, with prior Pieris stockholders owning approximately 11% on a diluted basis and prior Palvella stockholders (including investors in the private placement) holding approximately 89% of the combined company's outstanding common stock on a diluted basis. In connection with the closing of the merger, Pieris issued a non-transferable contingent value right (CVR) to Pieris shareholders of record immediately prior to the closing, which does not include the former holders of shares of Palvella or the private financing investors. Holders of the CVR will be entitled to receive payments from proceeds received by the combined company, if any, under Pieris' existing partnership agreements with Pfizer and Boston Pharmaceuticals, in addition to other potential licensing agreements involving certain of Pieris' legacy assets, as well as certain potential payments related to historical research and development tax credits, which may or may not be realized. TD Cowen served as lead placement agent and Cantor served as a placement agent for Palvella's concurrent financing. Troutman Pepper Hamilton Sanders LLP served as legal counsel to Palvella. Cooley LLP served as legal counsel to the placement agents. Stifel served as the exclusive financial advisor to Pieris and Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. served as legal counsel to Pieris. About Microcystic Lymphatic Malformations Microcystic LMs are a rare, chronically debilitating genetic disease caused by dysregulation of the phosphatidylinositol 3-kinase (PI3K)/mTOR pathway. The disease is characterized by malformed lymphatic vessels that protrude through the skin and persistently leak lymph fluid (lymphorrhea) and bleed, often leading to recurrent serious infections and cellulitis that can cause hospitalization. The natural history of microcystic LMs are persistent and progressive without spontaneous resolution, with symptoms generally worsening during life, including increases in the number and size of malformed vessels that lead to complications and lifetime morbidity. There are currently no FDA-approved treatments for the estimated more than 30,000 diagnosed patients with microcystic LMs in the United States. About Palvella Therapeutics Founded and led by rare drug disease drug development veterans, Palvella Therapeutics PVLA is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORINTM platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella's lead product candidate, QTORINTM 3.9% rapamycin anhydrous gel (QTORINTM rapamycin), is currently in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations (microcystic LMs) and a Phase 2 trial in cutaneous venous malformations. For more information, please visit www.palvellatx.com or follow the Company on LinkedIn. QTORINTM rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency. This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella and Pieris, as well as assumptions made by, and information currently available to, management of Palvella and Pieris. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, the sufficiency of the combined company's capital resources; the combined company's cash runway; the expected timing of the closing of the proposed transactions; statements regarding the potential of, and expectations regarding, Palvella's programs, including QTORINTM rapamycin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity; the expected timing of initiating, as well as the design of Palvella's Phase 2 clinical trial of QTORINTM rapamycin in cutaneous venous malformations. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the limited operating history of each company; the significant net losses incurred since inception; the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella's product candidates, including QTORINTM rapamycin; the outcome of early clinical trials for Palvella's product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella's limited experience in designing clinical trials and lack of experience in conducting clinical trials; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella's current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of the global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella and Pieris to protect their respective intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Pieris' most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, as well as the registration statement on Form S-4 filed with the SEC by Pieris in connection with the merger. Palvella and Pieris can give no assurance that the conditions to the proposed transactions will be satisfied. Except as required by applicable law, Palvella and Pieris undertake no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release. Palvella Therapeutics Contact Information Investors Wesley H. Kaupinen Founder and CEO, Palvella Therapeutics wes.kaupinen@palvellatx.com Media Stephanie Jacobson Managing Director, Argot Partners palvella@argotpartners.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Shoplifting is a growing blight on brick-and-mortar retailers globally and across the state, and San Francisco’s stores are no exception. Brazen criminals feel they can shoplift by day or break-and-enter at night, typically without fear of arrest or reprisals. The closure of Bayside Market is a notable recent example , but there are many more, and with stores operating on knife-edge margins, competing against online stores with few such concerns, the next theft could be the last. With little help from over-stretched police, despite a recent 911 response center $9 million renovation , and unresponsive politicians, stores have to take their own preventative steps. Larceny rates, which includes shoplifting, have been on the rise for years in San Francisco, despite a recent dip . Beyond more barriers and security guards, retailers aim to tilt the battle in their favor, replacing current security systems with smart and AI-powered systems. These improve on traditional models by being able to differentiate between suspicious and normal behavior. They can identify repeat offenders through facial ID, and other methods since many thieves wear hoods or masks, such as their clothing or walking gait. In grocery stores, AI is already used at self-checkouts in Walmart to monitor people “fake-scanning” high value goods and trying to escape without paying. Linked camera systems can follow and link criminals to their vehicles through license plate recognition. And in the integrated Internet of Things smart systems of the near future, they could track them through related big data services, identifying their mobile devices as they move, or even social media posts (not all criminals are particularly smart, after all). The question of privacy remains an obvious concern for shoppers. And, despite the recent state political opposition toward AI safety legislation, AI-powered security cameras are being rolled out around San Francisco stores today to save their stores for tomorrow. For those facing crime today, AI security systems and cameras help reduce the workload on the operators, alerting them to suspicious activity automatically. That means security teams can spend more time on the floor, being guided to incidents by the AI. Artificial intelligence can also perform behavior analysis that identifies and tracks suspicious activity, such as people loitering in one part of a store, or unusual movements like an accomplice trying to divert staff attention so the criminal can act unseen. Additional benefits of AI include the camera’s ability to identify the sound of breaking glass or gunshots and alert security teams and staff to the safest course of action, and call the police automatically. Beyond crime, an additional benefit of AI is footfall monitoring tools that can identify choke points or empty zones in the store, helping improve layouts for security, safety, and to improve sales. While the cost of a new AI security system for a large store can be substantial, the cost can be offset by lower insurance premiums, reduced crime, improved recovery rates, and greater visitor numbers as the store becomes a safer place. While crime continues largely unabated all shoppers are used to seeing cameras and their faces on screens by the tills. For stores, large and small, the arrival of AI comes as an invisible addition, but one that can improve their chances of survival and help drive growth through a range of AI-powered services. As mentioned at the start of this piece, shoplifting is a global problem, but retailers around the world are already seeing the benefits of AI in action. Across California and the wider US, Sam’s Club is installing AI-powered cameras in a trial to prevent shoplifting. It checks photos of their basket or cart against what they paid for at the checkout. British retail chain Co-op is using it in multiple stores to detect if someone has left without paying for an item, or whether someone has entered with a concealed weapon. And closer to home, a Chicago store reported a 50% drop in theft after installing AI-powered security cameras that monitor people making attempts to pocket or conceal items before leaving the store without paying. Given the distressed state of many malls, strip malls, and even high-end outlets, AI, already used successfully in medicine, insurance and many other areas of our lives is coming to a store near you to help prevent crime and keep the store alive, something that most shoppers will welcome. *The San Francisco Examiner newsroom and editorial were not involved in the creation of this content.Barrick Gold Corp. stock falls Wednesday, underperforms market
Revolve to present at the Small Cap Growth Virtual Investor Conference December 5thMike McDaniel stepped in to keep Dolphins from trading veteran DT Calais Campbell to RavensGMOs are food poison – Agric experts protestNEW YORK (AP) — Same iconic statue, very different race. With two-way star Travis Hunter of Colorado and Boise State running back Ashton Jeanty leading the field, these certainly aren't your typical Heisman Trophy contenders. Sure, veteran quarterbacks Dillon Gabriel from top-ranked Oregon and Cam Ward of No. 15 Miami are finalists for college football's most prestigious award as well, but the 90th annual ceremony coming up Saturday night at Lincoln Center in New York City offers a fresh flavor this year. To start with, none of the four are from the powerhouse Southeastern Conference, which has produced four of the past five Heisman winners — two each from Alabama and LSU. Jeanty, who played his home games for a Group of Five team on that peculiar blue turf in Idaho more than 2,100 miles from Manhattan, is the first running back even invited to the Heisman party since 2017. After leading the country with 2,497 yards rushing and 29 touchdowns, he joined quarterback Kellen Moore (2010) as the only Boise State players to be named a finalist. “The running back position has been overlooked for a while now," said Jeanty, who plans to enter the 2025 NFL draft. "There's been a lot of great running backs before me that should have been here in New York, so to kind of carry on the legacy of the running back position I think is great. ... I feel as if I'm representing the whole position.” With the votes already in, all four finalists spent Friday conducting interviews and sightseeing in the Big Apple. They were given custom, commemorative watches to mark their achievement. “I'm not a watch guy, but I like it,” said Hunter, flashing a smile. The players also took photos beneath the massive billboards in Times Square and later posed with the famous Heisman Trophy, handed out since 1935 to the nation's most outstanding performer. Hunter, the heavy favorite, made sure not to touch it yet. A dominant player on both offense and defense who rarely comes off the field, the wide receiver/cornerback is a throwback to generations gone by and the first full-time, true two-way star in decades. On offense, he had 92 catches for 1,152 yards and 14 touchdowns this season to help the 20th-ranked Buffaloes (9-3) earn their first bowl bid in four years. On defense, he made four interceptions, broke up 11 passes and forced a critical fumble that secured an overtime victory against Baylor. Hunter played 688 defensive snaps and 672 more on offense — the only Power Four conference player with 30-plus snaps on both sides of the ball, according to Colorado research. Call him college football’s answer to baseball unicorn Shohei Ohtani. “I think I laid the ground for more people to come in and go two ways,” Hunter said. “It starts with your mindset. If you believe you can do it, then you'll be able to do it. And also, I do a lot of treatment. I keep up with my body. I get a lot of recovery.” Hunter is Colorado's first Heisman finalist in 30 years. The junior from Suwanee, Georgia, followed flashy coach Deion Sanders from Jackson State, an HBCU that plays in the lower level FCS, to the Rocky Mountains and has already racked up a staggering combination of accolades this week, including The Associated Press player of the year. Hunter also won the Walter Camp Award as national player of the year, along with the Chuck Bednarik Award as the top defensive player and the Biletnikoff Award for best wide receiver. “It just goes to show that I did what I had to do,” Hunter said. Next, he'd like to polish off his impressive hardware collection by becoming the second Heisman Trophy recipient in Buffaloes history, after late running back Rashaan Salaam in 1994. “I worked so hard for this moment, so securing the Heisman definitely would set my legacy in college football,” Hunter said. “Being here now is like a dream come true.” Jeanty carried No. 8 Boise State (12-1) to a Mountain West Conference championship that landed the Broncos the third seed in this year's College Football Playoff. They have a first-round bye before facing the SMU-Penn State winner in the Fiesta Bowl quarterfinal on New Year’s Eve. The 5-foot-9, 215-pound junior from Jacksonville, Florida, won the Maxwell Award as college football’s top player and the Doak Walker Award for best running back. Jeanty has five touchdown runs of at least 70 yards and has rushed for the fourth-most yards in a season in FBS history — topping the total of 115 teams this year. He needs 132 yards to break the FBS record set by Heisman Trophy winner Barry Sanders at Oklahoma State in 1988. In a pass-happy era, however, Jeanty is trying to become the first running back to win the Heisman Trophy since Derrick Henry for Alabama nine years ago. In fact, quarterbacks have snagged the prize all but four times this century. Gabriel, an Oklahoma transfer, led Oregon (13-0) to a Big Ten title in its first season in the league and the No. 1 seed in the College Football Playoff. The steady senior from Hawaii passed for 3,558 yards and 28 touchdowns with six interceptions. His 73.2% completion rate ranks second in the nation, and he's attempting to join quarterback Marcus Mariota (2014) as Ducks players to win the Heisman Trophy. “I think all the memories start to roll back in your mind,” Gabriel said. Ward threw for 4,123 yards and led the nation with a school-record 36 touchdown passes for the high-scoring Hurricanes (10-2) after transferring from Washington State. The senior from West Columbia, Texas, won the Davey O’Brien National Quarterback of the Year award and is looking to join QBs Vinny Testaverde (1986) and Gino Torretta (1992) as Miami players to go home with the Heisman. “I just think there's a recklessness that you have to play with at the quarterback position,” Ward said. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football
B.C. Premier David Eby vows to seek out new export opportunities in wake of Trump tariff planNone
Revolve to present at the Small Cap Growth Virtual Investor Conference December 5th
Friendly reminder |
The authenticity of this information has not been verified by this website and is for your reference only. Please do not reprint without permission. If authorized by this website, it should be used within the scope of authorization and marked with "Source: this website". |
Special attention |
Some articles on this website are reprinted from other media. The purpose of reprinting is to convey more industry information, which does not mean that this website agrees with their views and is responsible for their authenticity. Those who make comments on this website forum are responsible for their own content. This website has the right to reprint or quote on the website. The comments on the forum do not represent the views of this website. If you need to use the information provided by this website, please contact the original author. The copyright belongs to the original author. If you need to contact this website regarding copyright, please do so within 15 days. |